{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001104506","name":"INSMED Inc","summary":"Insmed is a global biopharmaceutical company developing and commercializing therapies for serious diseases across three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. Its two commercial products are ARIKAYCE (amikacin liposome inhalation suspension) for MAC lung disease, approved in the US, EU, and Japan, and BRINSUPRI (brensocatib tablets) for non-cystic fibrosis bronchiectasis, approved in the US and EU in 2025. Its pipeline includes TPIP, INS1148, and gene therapies INS1201 and INS1202.","people":[],"products":[{"name":"ARIKAYCE","type":"hardware","description":"Amikacin liposome inhalation suspension approved in the US, EU, and Japan for MAC lung disease treatment in refractory adult patients."},{"name":"BRINSUPRI","type":"hardware","description":"Brensocatib 25 mg and 10 mg oral once-daily tablets approved in the US and EU for non-cystic fibrosis bronchiectasis in patients 12 years and older."},{"name":"TPIP","type":"hardware","description":"Inhaled dry powder formulation of treprostinil prodrug treprostinil palmitil in clinical development for PH-ILD, PAH, PPF, and IPF."},{"name":"INS1148","type":"hardware","description":"Phase 2-ready monoclonal antibody targeting SCF248, acquired in December 2025, planned for development in interstitial lung disease and moderate to severe asthma."},{"name":"Brensocatib (HS indication)","type":"service","description":"Small molecule oral reversible DPP1 inhibitor in Phase 2b development for hidradenitis suppurativa."},{"name":"INS1201","type":"hardware","description":"Intrathecally delivered gene therapy in Phase 1 clinical study for patients with Duchenne muscular dystrophy."},{"name":"INS1202","type":"hardware","description":"Intrathecally delivered gene therapy in Phase 1 clinical study for patients with amyotrophic lateral sclerosis."}],"partnerships":[{"partner_name":"AstraZeneca","partnership_type":"licensing","description":"Insmed licensed brensocatib from AstraZeneca in October 2016.","start_date":null}],"affiliations":[],"origin":{"leaf":"5dd0564e7d0a00f9a9ffd74a09299e1f491a90bf43197bb2de92ec0075ba633f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"3f718750109b562a3806b7e4303200892f2ca08c6d6d0a60516b1d7396276395","parent":"bef748185be0dee4f219ffbc6fa39c8732a4ffbd2510391dde8d92894999848b","source":"0001104506-26-000009","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":125,"hourly_limit":500,"remaining":375,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}